Literature DB >> 8392310

Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.

R Geleziunas1, E J Arts, F Boulerice, H Goldman, M A Wainberg.   

Abstract

We investigated whether cells derived from the fetal central nervous system can support productive infection by a human immunodeficiency virus type 1 (HIV-1) isolate termed UHC-1, produced by a cellular clone derived from HIV-1 strain HIV-IIIB chronically infected U-937 promonocytic cells, and what the effect of nucleoside analogs might be on viral replication in this system. Fractionation of human fetal brain tissue into two different populations, enriched for either astrocytes or macrophages, showed that only the latter were able to support productive UHC-1 replication and generation of detectable progeny virus. Pretreatment of fetal brain macrophages with either of two nucleoside analogs, 3'-azido-3'-deoxythymidine (AZT) or the (-) enantiomer of 2'-deoxy-3'-thiacytidine, efficiently blocked production of progeny virus. Generation of unintegrated proviral DNA and HIV-1 transcripts were inhibited by pretreatment of fetal brain macrophages with 1 microM AZT. Administration of AZT at 24 h postinfection led to a slight reduction in viral transcript levels and viral progeny production by day 15 postinfection; however, brain macrophages under these conditions did not contain detectable amounts of unintegrated viral DNA. These results suggest that AZT may interfere with the accumulation of unintegrated HIV-1 DNA in brain macrophages. This is the first demonstration that nucleoside analogs are able to block HIV-1 replication in primary cultures of brain cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392310      PMCID: PMC187957          DOI: 10.1128/AAC.37.6.1305

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.

Authors:  S Koenig; H E Gendelman; J M Orenstein; M C Dal Canto; G H Pezeshkpour; M Yungbluth; F Janotta; A Aksamit; M A Martin; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

3.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.

Authors:  C A Wiley; R D Schrier; J A Nelson; P W Lampert; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Human T-cell lymphotropic virus type III infection of the central nervous system. A preliminary in situ analysis.

Authors:  M H Stoler; T A Eskin; S Benn; R C Angerer; L M Angerer
Journal:  JAMA       Date:  1986-11-07       Impact factor: 56.272

Review 6.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.

Authors:  R W Price; B Brew; J Sidtis; M Rosenblum; A C Scheck; P Cleary
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

7.  "Sternberg-reed" giant cells of Hodgkin's Disease: cultivation in vitro, heterotransplantation, and characterization as neoplastic macrophages.

Authors:  H S Kaplan; S Gartner
Journal:  Int J Cancer       Date:  1977-04-15       Impact factor: 7.396

8.  Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

Authors:  R Yarchoan; G Berg; P Brouwers; M A Fischl; A R Spitzer; A Wichman; J Grafman; R V Thomas; B Safai; A Brunetti
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

Authors:  H Mitsuya; R F Jarrett; M Matsukura; F Di Marzo Veronese; A L DeVico; M G Sarngadharan; D G Johns; M S Reitz; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

View more
  9 in total

1.  Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures.

Authors:  P K Peterson; G Gekker; S Hu; C C Chao
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  D Lamarre; G Croteau; E Wardrop; L Bourgon; D Thibeault; C Clouette; M Vaillancourt; E Cohen; C Pargellis; C Yoakim; P C Anderson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.

Authors:  Roberta Bona; Mauro Andreotti; Viviana Buffa; Pasqualina Leone; Clementina Maria Galluzzo; Roberta Amici; Lucia Palmisano; Maria Grazia Mancini; Zuleika Michelini; Roberto Di Santo; Roberta Costi; Alessandra Roux; Yves Pommier; Christophe Marchand; Stefano Vella; Andrea Cara
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Sébastien Wurtzer; Séverine Compain; Henri Benech; François Clavel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

7.  Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.

Authors:  E J Arts; J P Marois; Z Gu; S F Le Grice; M A Wainberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

9.  Lamivudine Inhibits the Replication of ALV-J Associated Acutely Transforming Virus and its Helper Virus and Tumor Growth In vitro and In vivo.

Authors:  Yixin Wang; Shuzhen Xu; Sifei Li; Hongqin Su; Shuang Chang; Yang Li; Xiaolong Sun; Peng Zhao; Zhizhong Cui
Journal:  Front Microbiol       Date:  2015-12-01       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.